| Aug 1 |
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 1 |
Ardelyx: Q2 Earnings Snapshot
|
| Aug 1 |
Ardelyx GAAP EPS of -$0.07 beats by $0.03, revenue of $73.22M beats by $18.19M
|
| Aug 1 |
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 31 |
Ardelyx Q2 2024 Earnings Preview
|
| Jul 31 |
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
|
| Jul 29 |
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
|
| Jul 25 |
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
|
| Jul 18 |
Ardelyx sues CMS over revamped kidney disease drug payment bundle
|
| Jul 18 |
Ardelyx sues U.S. over Medicare policy proposal
|
